Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Int. braz. j. urol ; 38(6): 802-808, Nov-Dec/2012. tab, graf
Article in English | LILACS | ID: lil-666014



To evaluate histological alterations in prepuce of patients with phimosis submitted to topic treatment with betamethasone in association with hyaluronidase. Materials and Methods

We studied sixty patients (mean age 4.5), presenting true phimosis and treated with a topical treatment with betamethasone cream (0.2%) + hyaluronidase. The parents of seven of these patients opted for circumcision (control group). The other fifty-three patients were submitted to clinical treatment. The samples were stained with Weigert's resorcin-fuchsin (analysis of the elastic fibers) and Picro-Sirius Red, for analysis of the collagen. The volumetric density of the elastic fibers was determined by stereological methods. Results

Only eight (15%) of the fifty-three patients submitted to topical treatment presented failure, being indicated for circumcision (histological analysis). We observed an increase of the collagen type III of the patients submitted to topical treatment. The quantification showed a reduction of the volumetric density of the prepuce's elastic fibers of the patients submitted to the cream treatment, when compared to the control group (p = 0.056). The volumetric density of the elastic fibers of the prepuce at the group not submitted to topical treatment showed an average of 14.60% (11.06 to 21.64%); in the group submitted to the cream treatment, the volumetric density of the elastic fibers of the prepuce showed an average of 10.34% (3.45 to 17.9%). Conclusion

The topical treatment of phimosis with betamethasone 0.2% + hyaluronidase had a success rate of 85%. Patients with failure of the topical treatment with steroid had histological alterations in the prepuce. .

Child , Child, Preschool , Humans , Male , Betamethasone/therapeutic use , Foreskin/pathology , Glucocorticoids/therapeutic use , Hyaluronoglucosaminidase/therapeutic use , Phimosis/drug therapy , Phimosis/pathology , Administration, Topical , Elastic Tissue/drug effects , Elastic Tissue/pathology , Foreskin/drug effects , Time Factors , Treatment Failure
Int. braz. j. urol ; 37(3): 314-319, May-June 2011. tab
Article in English | LILACS | ID: lil-596005


PURPOSE: To compare the efficacy of three different formulations containing Betamethasone Valerate versus placebo in the topical treatment of phimosis. As a secondary goal, we compared the outcomes after 30 and 60 days of treatment. MATERIALS AND METHODS: Two hundred twenty boys aged 3 to 10 years old with clinical diagnosis of phimosis were enrolled. Patients were randomized to one of the following groups: Group 1: Betamethasone Valerate 0.2 percent plus Hyaluronidase; Group 2: Betamethasone Valerate 0.2 percent; Group 3: Betamethasone Valerate 0.1 percent or Group 4: placebo. Parents were instructed to apply the formula twice a day for 60 days and follow-up evaluations were scheduled at 30, 60 and 240 days after the first consultation. Success was defined as complete and easy foreskin retraction. RESULTS: One hundred ninety-five patients were included at our final analysis. Group 1 (N = 54), 2 (N = 51) and 3 (N = 52) had similar success and improvement rates, all treatment groups had higher success rates than placebo(N = 38). After 60 days of treatment, total and partial response rates for Groups 1, 2 and 3 were 54.8 percent and 40.1 percent, respectively, while placebo had a success rate of 29 percent. Success and improvement rates were significantly better in 60 days when compared to 30 days. CONCLUSIONS: Betamethasone Valerate 0.1 percent, 0.2 percent and 0.2 percent in combination with Hyaluronidase had equally higher results than placebo in the treatment of phimosis in boys from three to ten years-old. Patients initially with partial or no response can reach complete response after 60 days of treatment.

Child , Child, Preschool , Humans , Male , /administration & dosage , Glucocorticoids/administration & dosage , Hyaluronoglucosaminidase/administration & dosage , Phimosis/drug therapy , Administration, Topical , Double-Blind Method , Drug Administration Schedule , Prospective Studies , Treatment Outcome
Int. braz. j. urol ; 36(1): 75-85, Jan.-Feb. 2010. ilus, graf, tab
Article in English | LILACS | ID: lil-544078


Purpose: To compare the efficacy and costs of circumcision versus topical treatment using a prospective pharmacoeconomic protocol. Materials and methods: We treated 59 patients (3-10 years of age) randomized into two groups: 29 underwent an 8-week course of topical treatment with 0.2 percent betamethasone-hyaluronidase cream twice a day; and 30 underwent circumcision. Topical treatment success was defined as complete exposure of the glans. In cases of treatment failure, circumcision was performed and its cost imputed to that of the initial treatment. The pharmacoeconomic aspects were defined according to the Brazilian National Public Health System database and the Brazilian Community Pharmacies Index. Results: The two groups were statistically similar for all clinical parameters evaluated. Topical treatment resulted in complete exposure of the glans in 52 percent of the patients. Topical treatment was associated with preputial pain and hyperemia. However, treatment suspension was unnecessary. Minor complications were observed in 16.6 percent of the surgical group patients. The mean cost per patient was US$ 53.70 and US$ 125.20, respectively, for topical steroid treatment (including the costs related to treatment failure) and circumcision. The total costs were US$ 2,825.32 and US$ 3,885.73 for topical treatment and circumcision, respectively. Conclusions: Topical treatment of phimosis can reduce costs by 27.3 percent in comparison with circumcision. Therefore, topical treatment of phimosis should be considered prior to the decision to perform surgery.

Child , Child, Preschool , Humans , Male , Betamethasone/therapeutic use , Circumcision, Male/methods , Hyaluronoglucosaminidase/therapeutic use , Phimosis/drug therapy , Phimosis/surgery , Administration, Topical , Betamethasone/administration & dosage , Cost-Benefit Analysis , Circumcision, Male/economics , Hyaluronoglucosaminidase/administration & dosage , Prospective Studies , Phimosis/economics , Treatment Outcome
Int. braz. j. urol ; 31(4): 370-374, July-Aug. 2005. ilus, tab
Article in English | LILACS | ID: lil-412897


OBJECTIVES: To correlate topical steroidal treatment of stenosed foreskin with the different degrees of glans exposure and the length of time the ointment is applied. MATERIALS AND METHODS: We studied 95 patients with phimosis, divided according to the degree of foreskin retraction. Group A presented no foreskin retraction, group B presented exposure of only the urethral meatus, group C presented exposure of half of the glans, and group D presented exposure of the glans, which was incomplete because of preputial adherences to the coronal sulcus. Patients were submitted to application of 0.05 percent betamethasone ointment on the distal aspect of the prepuce twice daily for a minimum of 30 days and a maximum of 4 months. RESULTS: Of 95 patients, 10 (10.52 percent) abandoned the treatment and 15 patients in groups C and D were excluded from the study. Among the remaining 70 patients, only 4 patients (5.7 percent) in group A did not obtain adequate glans exposure after treatment. In group A (38 patients), fully retractable foreskins were obtained in 19 patients (50 percent) after 1 month of treatment. In group B (28 patients), fully retractable foreskins were obtained in 18 patients (64.2 percent) after 1 month. CONCLUSIONS: Treatment was successful in 94.2 percent of patients, irrespective of the type of foreskin anatomy. The improvement may require several months of treatment. Patients with impossibility of urethral meatus exposure present around 10 percent treatment failure.

Infant , Child, Preschool , Child , Adolescent , Humans , Male , Betamethasone/therapeutic use , Glucocorticoids/therapeutic use , Phimosis/drug therapy , Severity of Illness Index , Treatment Outcome